Back to search results

Remote Monitoring for Progressive Supranuclear Palsy (PSP)

This study is looking at how well wearable sensors and digital health tools can track falls and changes in movement, speech, and thinking abilities in people with Progressive Supranuclear Palsy (PSP), Parkinson's disease, or Multiple System Atrophy (MSA). It's also open to healthy volunteers. The study aims to see if these remote monitoring tools are practical to use over about one year. You would be using a wearable sensor and a study-provided tablet to complete assessments from home, with some virtual meetings with the study team. The study plans to enroll about 85 participants aged 18 to 89 who can read and speak English.

Study design
This is an observational study, meaning it watches and records information without giving any specific treatments. It plans to include about 85 participants.
What's involved
You would wear a sensor daily and complete monthly supervised remote assessments, including gait and balance tasks, and cognitive tests on a tablet. More extensive virtual testing would occur every three months.
Compensation
Not stated in the trial record.
Follow-up
Participants with PSP and MSA will be monitored for approximately one year. Parkinson's and healthy control participants will be seen once at baseline only.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04753320

Remote Monitoring in Progressive Supranuclear Palsy (PSP)

Not Yet Recruiting
Not specifiedAges 18–89Observational
Massachusetts General Hospital
~85 participants
Updated 2026-07-29 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Primary feasibility outcome
Measured over 12 months

Conditions

Progressive Supranuclear Palsy
Parkinson Disease
MSA - Multiple System Atrophy

Explore related trials

Multiple System AtrophyParkinson DiseaseProgressive Supranuclear Palsy

Where it's being run

2 sites across 2 states
Maryland1
Massachusetts1

Study leadership

  • Anne-Marie A Wills, MD MPH · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital

Who to contact

Yvonne Kim, BS
[email protected]
617-643-2400
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Clinical diagnosis of possible or probable PSP phenotype as defined by the 2017 MDS criteria, clinical diagnosis of at least probable PD as defined by the 2015 MDS criteria, or clinical diagnosis of at least probable MSA as defined by the 2022 MDS criteria, or healthy controls.
Male or female, aged 18 to 89 years, inclusive.
Fluent in reading and speaking English.
Capable of providing informed consent based on the investigator's judgment.
Able to comply with the protocol based on the investigator's judgment.
Able to walk 10 feet unassisted.
With access to a caregiver who is able to assist with all study-related procedures.

Exclusion

Any neurological, medical, or psychiatric condition that would preclude participation in study activities based on the investigator's judgment.
A history of frequent falls defined as more than 5 falls/month or requirement of a walker to ambulate safely.

What this trial measures

  • Primary feasibility outcome12 months

    Compliance will be calculated as the number of participants who wear their PAMSys pendant sensors at least 16 hours/day for at least 180 days and complete at least 80% of their scheduled monthly sensor and tablet derived motor, speech, and cognitive assessments through their 6 month visit.